News
LAB
2.360
-2.48%
-0.060
Health Care Sector Update for 04/25/2024: LAB, PRGO, BMY, AZN
NASDAQ · 3h ago
Standard Biotools announces operational restructuring plan including headcount reduction
Standard BioTools Inc. Has initiated a restructuring plan to improve operational efficiency and reduce operating costs. The company has implemented a reduction of approximately 10% of its total workforce. The restructuring plan is expected to generate annualized operating expense savings of $45M to $50M in fiscal 2025.
Seeking Alpha · 10h ago
Standard BioTools: Workforce Cut and Management Reshuffle Post-Merger
TipRanks · 11h ago
STANDARD BIOTOOLS INC: REDUCTION-IN-FORCE INCLUDING ELIMINATION OF CERTAIN SENIOR MANAGEMENT POSITIONS
Reuters · 11h ago
Standard BioTools Plans Operational Restructuring; Implements Reduction Of Approximately 10% Of Its Total Workforce
Benzinga · 11h ago
STANDARD BIOTOOLS INC - MAJORITY OF COST TAKEOUT TO OCCUR IN SECOND HALF OF 2024
Reuters · 11h ago
Standard BioTools (NASDAQ:LAB shareholders incur further losses as stock declines 6.3% this week, taking five-year losses to 82%
Standard BioTools Inc. (NASDAQ:LAB) has lost US$65m in the past 7 days. The share price of the company has dropped 13% over the last five years. The company is expected to grow revenue but has lost money and doesn't grow revenue. Standard BioTools shareholders have received a total shareholder return of 53% in the last year. It's a good reminder of the importance of diversification.
Simply Wall St · 2d ago
Weekly Report: what happened at LAB last week (0415-0419)?
Weekly Report · 3d ago
Standard BioTools Initiated at Buy by TD Cowen
Dow Jones · 04/16 11:24
Standard BioTools Price Target Announced at $3.50/Share by TD Cowen
Dow Jones · 04/16 11:24
TD Cowen Initiates Coverage On Standard BioTools with Buy Rating, Announces Price Target of $3.5
Benzinga · 04/16 11:15
STANDARD BIOTOOLS INC <LAB.O>: TD COWEN INITIATES COVERAGE WITH BUY RATING ; TARGET PRICE $3.5
Reuters · 04/16 11:12
U.S. RESEARCH ROUNDUP-Advanced Micro Devices, Kroger, Tyson Foods
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Advanced Micro Devices, Kroger and Tyson Foods among companies with new targets. Analysts raise ratings and target prices on several companies. Boeing, Caterpillar and AIG among those with targets raised.
Reuters · 04/16 07:18
Weekly Report: what happened at LAB last week (0408-0412)?
Weekly Report · 04/15 09:16
Is It Time To Consider Buying Standard BioTools Inc. (NASDAQ:LAB)?
Standard BioTools Inc. (NASDAQ:LAB) led the NASDAQGS gainers with a large price hike in the past week. The company is inching closer to its yearly highs. Standard BioTools is overvalued by 38% compared to its intrinsic value. Is there still an opportunity to buy the stock? We look at the company's outlook and valuation to see if the opportunity still exists.
Simply Wall St · 04/09 10:04
Weekly Report: what happened at LAB last week (0401-0405)?
Weekly Report · 04/08 09:17
Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging
New solutions add automation and flexibility to the Imaging Mass Cytometry™ workflow on the Hyperion XTi™ Imaging System. Standard BioTools Inc. Is committed to unleashing tools to accelerate breakthroughs in human health. The company is based in San Francisco, California.
Barchart · 04/08 07:00
After Hours Most Active for Apr 5, 2024 : T, INTC, PDD, GRAB, LAB, PCG, QQQ, SE, VZ, XOM, PARA, PFE
NASDAQ · 04/05 20:24
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC) and Standard BioTools (LAB)
TipRanks · 04/04 12:10
Standard BioTools Price Target Announced at $3.25/Share by Jefferies
Dow Jones · 04/04 11:31
More
Webull provides a variety of real-time LAB stock news. You can receive the latest news about STANDARD BIOTOOLS INC through multiple platforms. This information may help you make smarter investment decisions.
About LAB
Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. The Company's segments include Proteomics and Genomics. The Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. The Company provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The Company also provides differentiated multi-omics tools for research.